Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC)

被引：0
|
作者：
Yan Li
Hui Shi
Zhenjun Zhao
Minghui Xu
机构：
[1] Yantai University,College of Life Sciences
[2] Sun Yat-sen University,School of Life Sciences
来源：
BMC Urology | / 22卷
关键词：
Differentially expressed genes (DEGs); Castration-resistant prostate cancer (CRPC); Cell cycle; Cell proliferation; Prostate gland development;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)
    Tsao, Che-Kai
    Galsky, Matthew D.
    Small, Alexander C.
    Yee, Tiffany
    Oh, William K.
    BJU INTERNATIONAL, 2012, 110 (11) : 1580 - 1588
  • [32] Testosterone defining prognosis and predicting response in castration-resistant prostate cancer (CRPC)
    Gomez de Liano, A.
    Reig, O.
    Mellado, B.
    Martin, C.
    Sancho, G.
    Palou, J.
    Anguera, G.
    Arqueros, C.
    Condori, D.
    Maroto-Rey, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S702 - S702
  • [33] Alterations of androgen action in castration-resistant prostate cancer (CRPC) and in abnormalities of virilization
    McPhaul, Michael J.
    Malewska, Alicia
    Vilaythong, Jill
    Glickman, Stephen E.
    Marcelli, Marco
    Sharifi, Nima
    Auchus, Richard J.
    ENDOCRINE JOURNAL, 2010, 57 : S264 - S264
  • [34] Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC)
    Nabhan, C.
    Tolzien, K.
    Lestingi, T. M.
    Galvez, A.
    Bitran, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] A resource-based mechanistic framework for castration-resistant prostate cancer (CRPC)
    Vibishan, B.
    Harshavardhan, B. V.
    Dey, Sutirth
    JOURNAL OF THEORETICAL BIOLOGY, 2024, 587
  • [36] Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC).
    Morgans, Alicia Katherine
    Graves, Amy J.
    Penson, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC)
    Pal, Sumanta Kumar
    Patel, Jaymala
    He, Miaoling
    Foulk, Brad
    Kraft, Katherine
    Smirnov, Denis A.
    Twardowski, Przemyslaw
    Kortylewski, Marcin
    Bhargava, Vipul
    Jones, Jeremy O.
    CANCER, 2018, 124 (06) : 1216 - 1224
  • [38] Zweitlinientherapie beim kastrationsresistenten Prostatakarzinom (CRPC)Second line therapy for castration-resistant prostate cancer (CRPC)
    B. Molitor
    C. Börgermann
    Der Urologe, 2012, 51 (3): : 357 - 362
  • [39] Darolutamide For Castration-Resistant Prostate Cancer
    Bastos, Diogo A.
    Antonarakis, Emmanuel S.
    ONCOTARGETS AND THERAPY, 2019, 12 : 8769 - 8777
  • [40] Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC)
    Karakunnel, J. J.
    Gulley, J. L.
    Arlen, P.
    Mulquin, M.
    Wright, J.
    Turkbey, I. B.
    Choyke, P.
    Figg, W. D.
    Dahut, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345